Biogen Inc. (BIIB)

302.60
0.26 0.09
NASDAQ : Health Technology
Prev Close 302.86
Open 303.04
Day Low/High 299.71 / 304.68
52 Wk Low/High 215.78 / 374.99
Volume 895.56K
Avg Volume 1.97M
Exchange NASDAQ
Shares Outstanding 163.19M
Market Cap 49.19B
EPS 31.50
P/E Ratio 9.32
Div & Yield N.A. (N.A)

Fibocall: Technical Trading Texts

Mid-Caps Outperform, Funding 'Paycheck Protection', U.K. Vaccine Trials

Mid-Caps Outperform, Funding 'Paycheck Protection', U.K. Vaccine Trials

Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.

Jim Cramer: A Recession Might Be Good Medicine Right Now

Jim Cramer: A Recession Might Be Good Medicine Right Now

A bear market, if it gets us all to slow down, may be necessary to slow the coronavirus' spread -- but this doesn't mean I'm giving up. To the contrary.

Sangamo Therapeutics Shows Promise

Sangamo Therapeutics Shows Promise

Let's check out the charts of SGMO and come up with a trading strategy.

Real Money Post Industrial Average Holds Own Amid Covid-19 Selloff

Real Money Post Industrial Average Holds Own Amid Covid-19 Selloff

Amid a flood of corporate warnings over the coronavirus, all the major stock market indexes finished last month down 6.4% to 10.1%.

The Fed's Moves, Trading 5 Stocks, Coronavirus and the Market: Market Recon

The Fed's Moves, Trading 5 Stocks, Coronavirus and the Market: Market Recon

It's no secret that the Fed would like to get out of the short-term repo business.

Biogen Raised to Buy at Canaccord

4 Favorite Biotech Stock Picks for 2020

4 Favorite Biotech Stock Picks for 2020

The Medical Technology Stock Letter's top pick rose 357% in 2019.

Plenty of Reasons to Remain Bullish on Real Money Post Industrial Average

Plenty of Reasons to Remain Bullish on Real Money Post Industrial Average

Let's review 2019 performance of RMPIA in relation to stock indexes and see what's ahead.

Jim Cramer: Think Owning Tech Is Hard? Look at This Post-Impeachment Record

Jim Cramer: Think Owning Tech Is Hard? Look at This Post-Impeachment Record

A lot of the names that fell hard after the Clinton impeachment have been record earners since then.

Jim Cramer: Think Stocks Are Too Pricey? These Big Takeovers Prove They're Not

Jim Cramer: Think Stocks Are Too Pricey? These Big Takeovers Prove They're Not

We're seeing lots of companies snapping up their peers, and the market is applauding.

Real Money Post Industrial Average Exits October on Top

Real Money Post Industrial Average Exits October on Top

The RMPIA's 3.8% jump even beat the Nasdaq Composite Index's 3.7% October climb.

Jim Cramer: Nothing's Changed, Except the Prices

Jim Cramer: Nothing's Changed, Except the Prices

The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.

Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts

Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts

Breaking down an approach to the long side of this biotech stock.

Jim Cramer: Drug Stocks Are Too Cheap

Jim Cramer: Drug Stocks Are Too Cheap

These stocks are priced for total imperfection. That's just what you want.

Biogen Raised at Bernstein

Biogen Maintained at Neutral at JPMorgan

Big Biotech Receives Some Needed Shots in the Arm

Big Biotech Receives Some Needed Shots in the Arm

Biogen, Novartis and Bristol-Myers Squibb are among the drugmakers that gave investors reasons for cheer on Tuesday.

Jim Cramer: The Soundness of My Methods

Jim Cramer: The Soundness of My Methods

A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.

We Have a Market That Has Become a Little Extended

We Have a Market That Has Become a Little Extended

This looks like a normal pause within an uptrend.

Biogen Stock Soars on Alzheimer's Drug News

Biogen Stock Soars on Alzheimer's Drug News

BIIB also reported third quarter results Tuesday that easily beat the consensus both on the top and the bottom line.

China Trade Optimism, Do Boeing's Numbers Matter? Trading Apple: Market Recon

China Trade Optimism, Do Boeing's Numbers Matter? Trading Apple: Market Recon

There is a chance that Presidents Trump and Xi sign something when they meet up at the APEC summit this November in Santiago, Chile.

No Shortage of Candidates for the Next Portfolio of Losers

No Shortage of Candidates for the Next Portfolio of Losers

Dozens of beaten-up stocks could see tax-loss selling into the end of the year; here's a preview of some that could make up the next Tax Loss Selling Portfolio.

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

M&A Appetite in Pharma Has Proved Potent: Chart of the Day

With total deals trending toward hundreds of billions, investors may be eager to bet on who's next to be acquired.

5 Favorites for Biotech Stock Buyers

5 Favorites for Biotech Stock Buyers

For those with a long-term horizon, here are some top picks.

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

Real Money Post-Industrial Average Leads Major Indexes So Far for Year

In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.

Big Pharma Sees Pockets of Recent Insider Buying

Big Pharma Sees Pockets of Recent Insider Buying

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

3 Trends Driving This Earnings Season

3 Trends Driving This Earnings Season

With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.

High Flyers and Low Flyers

Equities are a bit higher across the board since our last update. Homebuilders continue to be in the green as 30-year mortgage rates hover near three-year lows. This is starting to have an effect as purchase application demand has posted its biggest...

Now at the Plate, Your Pinch Hitter, Bret Jensen

I am happy to be sitting back in for Doug Kass on the Daily Diary. I look forward to an active live chat arena today. We certainly have a lot of potential discussion topics. Second-quarter earnings reports will continue to hit the wires in a fast an...